Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02436993 |
Recruitment Status :
Recruiting
First Posted : May 7, 2015
Last Update Posted : July 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Carcinoma | Drug: Carboplatin Drug: Paclitaxel Drug: Bevacizumab Drug: Trastuzumab Drug: Pertuzumab | Phase 2 |
OBJECTIVES The study component is to evaluate the treatment response and toxicity of the protocol.
Objectives for treatment study component:
1.1 To estimate 2-year progression-free survival in patients with breast cancer with tumor more than 1 cm and/or with clinically detected lymph node treated with neoadjuvant weekly Carboplatin and Paclitaxel combined with Trastuzumab + Pertuzumab in HER2-positive disease or with Bevacizumab in HER2-negative disease.
1.2 To measure the microscopic complete pathological response (pCR) rates defined as ypT0 or ypTis tumors in patients treated with this regimen in the neoadjuvant setting.
1.3 To assess complete clinical response (cCR) rates after treatment by physical exam and imaging tests (ultrasonography, mammography, or magnetic resonance imaging) clinical objective response rate (by Response Evaluation Criteria In Solid Tumors (RECIST)) 1.4 To determine the toxicity of this regimen. 1.5 To determine treatment adherence and delivered dose intensity of this regimen.
1.6 To assess the correlation between pCR and cCR. 1.7 To determine the rate of breast conservation following neoadjuvant therapy. 1.8 Determine treatment efficacy according to subgroups defined according to stage and receptor status.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting |
Study Start Date : | April 2015 |
Estimated Primary Completion Date : | August 2040 |
Estimated Study Completion Date : | August 2040 |

Arm | Intervention/treatment |
---|---|
Experimental: Carboplatin+Paclitaxel+Bevacizumab (HER2-)
Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
|
Drug: Carboplatin
Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
Other Name: Paraplatin Drug: Paclitaxel 80 mg/m^2 IV over 1-3 hours weekly for 12 doses
Other Name: Taxol Drug: Bevacizumab 10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
Other Name: Avastin |
Experimental: Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)
Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
|
Drug: Carboplatin
Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
Other Name: Paraplatin Drug: Paclitaxel 80 mg/m^2 IV over 1-3 hours weekly for 12 doses
Other Name: Taxol Drug: Trastuzumab 4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
Other Name: Herceptin Drug: Pertuzumab 840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
Other Name: Perjeta |
- 2-year progression free survival in patients treated with weekly carboplatin and paclitaxel combined with either trastuzumab and pertuzumab for HER2-positive patients or bevacizumab for HER2-negative patients in the neoadjuvant setting [ Time Frame: 2 years ]Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death
- Clinical complete response rates [ Time Frame: 2 years ]Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange
- Pathologic complete response rates [ Time Frame: 2 years ]Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)
- Number of toxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) arm [ Time Frame: Up to 42 days after discontinued treatment ]This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.
- Number of toxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+) [ Time Frame: Up to 42 days after discontinued treatment ]This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven unilateral or bilateral primary breast carcinoma. (In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.)
- Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging) and/or with involved lymph node. In case of inflammatory disease, the extent of inflammation may be the measurable lesion.
- Documentation of inflammatory breast cancer
- Woman age > or = 18
- Performance status of 0-2 by Eastern Cooperative Oncology Group (ECOG) criteria
- Known HER2 status
-
Normal cardiac function must be documented within 90 days prior to registration. Result of ejection fraction must be above the normal limit of the institution. Echo or MUGA is encouraged pre-study.
a. Date of Echo or multigated acquisition (MUGA) (within 90 days)
-
Staging work-up prior to registration
- Date of physical examination (within 90 days)
- Date of bilateral mammogram (within 90 days)
- Date of breast ultrasound (within 90 days)
- Date of MRI breast (within 30 days)
- Chest X-ray or CT-Chest or CT/PET Scan that includes the Chest is also accepted (within 90 days)
- Other tests as clinically indicated
-
Laboratory requirements:
-
Hematology:
- Absolute Neutrophil Count (ANC) ≥ 1,500/μl
- Platelets ≥ 100,000/μl
-
Hepatic Function
- Total Bilirubin <1x upper limit of normal (ULN)
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2x ULN
-
Renal Function
- Creatinine <1.5x ULN
-
Proteinuria
- Urine dipstick for proteinuria <2+. Patients discovered to have ≥2+ proteinuria on dipstick should undergo a 24-hour urine collection and demonstrate ≤ 1g of protein in 24 hours.
- Negative pregnancy test for women of childbearing potential within 14 days prior to registration.
-
-
All patients must be informed of the investigational nature of this study and must sign and\give written informed consent in accordance with institutional and federal guidelines.
Exclusion Criteria:
- Evidence of distant metastasis
- Known or suspected congestive heart failure, angina pectoris requiring antianginal medication, or other clinically significant cardiac condition.
- Pregnant or nursing women may not participate due to the possibility of harm to fetus or nursing infants from this treatment regimen. Women of childbearing potential may not participate unless they have agreed to use an adequate contraceptive method throughout study treatment and for one month after completion of treatment.
- Male patients
- Pre-existing peripheral neuropathy of severity grade ≥ 2 (limiting instrumental activities of daily living).
- Incomplete wound healing.
- Active and significant bleeding
- Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol.
- Bone marrow depression or hematologic parameters in the range that would increase the risk for severe bleeding.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02436993
Contact: UC Irvine Health Chao Family Comprehensive Cancer Center | 1-877-UC-STUDY | UCstudy@uci.edu |
United States, California | |
UC Irvine Health/Chao Family Comprehensive Cancer Center | Recruiting |
Orange, California, United States, 92868 | |
Contact: Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center 877-827-8839 UCstudy@uci.edu |
Principal Investigator: | Rita Mehta, MD | University of California, Irvine |
Responsible Party: | Rita Sanghvi, Mehta, HS Clinical Professor, University of California, Irvine |
ClinicalTrials.gov Identifier: | NCT02436993 |
Other Study ID Numbers: |
UCI 14-67 2015-1888 ( Other Identifier: University of California, Irvine ) |
First Posted: | May 7, 2015 Key Record Dates |
Last Update Posted: | July 2, 2020 |
Last Verified: | June 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Neoadjuvant Treatment Carboplatin Paclitaxel |
Pertuzumab Trastuzumab Bevacizumab |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Bevacizumab Carboplatin Trastuzumab Pertuzumab Antineoplastic Agents, Phytogenic |
Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |